Mantle cell lymphomas lack expression of p27kip1, a cyclin-dependent kinase inhibitor

被引:97
|
作者
Quintanilla-Martinez, L
Thieblemont, C
Fend, F
Kumar, S
Pinyol, M
Campo, E
Jaffe, ES
Raffeld, M
机构
[1] NCI, Hematopathol Sect, Pathol Lab, NIH, Bethesda, MD 20892 USA
[2] Univ Barcelona, Hosp Clin Prov, Barcelona, Spain
来源
AMERICAN JOURNAL OF PATHOLOGY | 1998年 / 153卷 / 01期
基金
奥地利科学基金会;
关键词
D O I
10.1016/S0002-9440(10)65558-7
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
p27(Kip1) is a cyclin-dependent kinase inhibitor that regulates the decision to enter S phase or withdraw from the cell cycle. In resting cells, the level of p27(Kip1) provides an inhibitory threshold above which G1 cyclin D/E/cyclin-dependent kinases accumulate before activation; however, in cycling cells, p27(Kip1) protein is sequestered by high levels of active cyclin D/cyclin-dependent kinase 4 complexes. As a group, the cyclin-dependent kinase inhibitors have been proposed to act as tumor suppressor genes, and several members have been implicated in the pathogenesis of a variety of human cancers. We examined p27(Kip1) expression in 116 non-Hodgkin's lymphomas including 50 cases of MCL (40 typical and 10 blastic variants), 21 follicular lymphomas, 20 diffuse large B-cell lymphomas, 16 chronic lymphocytic leukemias, 8 marginal zone B-cell lymphomas, and 1 splenic marginal zone lymphoma, and correlated its expression with that of the proliferation marker Ki67 (MiB1) and with p53. p27(Kip1) gene structure was analyzed by Southern blot in the group of MCLs, In all cases of non-Hodgkin's lymphoma other than MCL, p27(Kip1) expression was inversely related to the proliferation index as measured by Ki67, In contrast, in typical MCL, p27(Kip1) expression was negative in 35 of 40 (88%) cases, irrespective of the proliferative rate (median 15%; range 2 to 90%). Paradoxically, in the blastic variant of MCL, 8 of 10 (80%) cases showed expression of p27(Kip1), despite a high proliferation rate (median 60%; range 52 to 100%). However, the staining in most of the cases was less intense than in the reactive T lymphocytes, Deletions of p27(Kip1) gene were not found in any of the 25 cases examined. p53 expression was found in 15 of 50 cases of MCL: 7 of 10 (70%) in the blastic variant and 8 of 40 (20%) in the typical MCL (70% vs. 20%, P < 0.0045), These results demonstrate that MCLs, in contrast to other non-Hodgkin's lymphomas and normal lymphoid tissue, fail to correlate p27(Kip1) expression with the proliferation rate. This peculiar uncoupling of p27(Kip1) protein expression from the proliferation rate may be related to the high levels of cyclin D1 expressed in MCL and is likely to have profound effects on cell cycle regulation and contribute to the pathogenesis of MCL.
引用
收藏
页码:175 / 182
页数:8
相关论文
共 50 条
  • [11] BRCA1 transactivates the cyclin-dependent kinase inhibitor p27Kip1
    Williamson, EA
    Dadmanesh, F
    Koeffler, HP
    ONCOGENE, 2002, 21 (20) : 3199 - 3206
  • [12] The prognosis in spindle-cell sarcoma depends on the expression of cyclin-dependent kinase inhibitor p27Kip1 and cyclin E
    Goto, Y
    Kawauchi, S
    Ihara, K
    Ikemoto, K
    Ohi, R
    Kawai, S
    Sasaki, K
    CANCER SCIENCE, 2003, 94 (05) : 412 - 417
  • [13] Expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27kip1 in hepatocellular carcinoma
    Ke-Jun Nan Zhao Jing Ling Gong Department of Medical Oncology
    World Journal of Gastroenterology, 2004, (10) : 1425 - 1430
  • [14] The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury
    Vuddhidej Ophascharoensuk
    Matthew L. Fero
    Jeremy Hughes
    James M. Roberts
    Stuart J. Shankland
    Nature Medicine, 1998, 4 : 575 - 580
  • [15] Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27Kip1 in epithelial ovarian cancer
    Hurteau, JA
    Allison, BM
    Brutkiewicz, SA
    Goebl, MG
    Heilman, DK
    Bigsby, RM
    Harrington, MA
    GYNECOLOGIC ONCOLOGY, 2001, 83 (02) : 292 - 298
  • [16] Expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27Kip1 in hepatocellular carcinoma
    Nan, Ke-Jun
    Jing, Zhao
    Gong, Ling
    WORLD JOURNAL OF GASTROENTEROLOGY, 2004, 10 (10) : 1425 - 1430
  • [17] The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury
    Ophascharoensuk, V
    Fero, ML
    Hughes, J
    Roberts, JM
    Shankland, SJ
    NATURE MEDICINE, 1998, 4 (05) : 575 - 580
  • [18] Prognostic value of the cyclin-dependent kinase inhibitor p27Kip1 in gastric cancer
    Müller, W
    Grabsch, H
    Takeno, S
    Noguchi, T
    Hommel, G
    Gabbert, HE
    ANTICANCER RESEARCH, 2000, 20 (3A) : 1787 - 1792
  • [19] Minimal requirements for the nuclear localization of p27Kip1, a cyclin-dependent kinase inhibitor
    Zeng, Y
    Hirano, K
    Hirano, M
    Nishimura, J
    Kanaide, H
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 274 (01) : 37 - 42
  • [20] The Cyclin-Dependent Kinase Inhibitor p27Kip1 is a Positive Regulator of Schwann Cell Differentiation In Vitro
    Honghui Li
    Huiguang Yang
    Yonghua Liu
    Weipeng Huan
    Shuangwei Zhang
    Gang Wu
    Qiuhui Lu
    Qiuhong Wang
    Youhua Wang
    Journal of Molecular Neuroscience, 2011, 45